Merck’s Oral Antiviral Data In COVID-19 May Change Pandemic Outlook
Merck/Ridgeback’s ribonucleoside analog shows nearly 50% reduction of risk for hospitalization or death in Phase III study. Firms will seek EUA in US; a contract is in place for 1.7 million courses of therapy.
You may also be interested in...
Chinese venture Brii seeks US emergency authorization for its antibody combo, as Chugai aims for wider use of its antibody cocktail in Japan and two other Chinese firms link up on an oral antiviral.
In this week's podcast edition of Five Must-Know Things: will a new oral antiviral be transformative for COVID?; OX40 drugs gain prominence in atopic dermatitis; J&J adds pace to RSV vaccine race; Sarepta leapfrogs Pfizer in DMD gene therapy; and how real-world evidence and randomized trials might go together.
Merck’s antiviral could play a big role, but only if it proves effective in broader settings, such as post-exposure prophylaxis.